Ruling in a suspect: the role of AP2S1 mutations in familial hypocalciuric hypercalcemia type 3.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Role of adaptin protein complexes in intracellular trafficking and their impact on diseases.Bioengineered · 2021
   Article
2. Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects.Human molecular genetics · 2015
   Article
3. Rare diseases in clinical endocrinology: a taxonomic classification system.Journal of endocrinological investigation · 2015
   Article

Corrections and comments

• Comment on
  Identification of AP2S1 mutation and effects of low calcium formula in an infant with hypercalcemia and hypercalciuria.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as